KeyBanc raises Huntsman stock price target on merger synergies

KeyBanc raised its Huntsman price target to $13 from $12 and maintained an Overweight rating, citing a pending merger with OLN expected to close in two to three months and synergies valued at $6 per share on a net-present-value basis. Huntsman’s Q3 2026 revenue of $1.72 billion beat the $1.61 billion forecast, while EPS of $0.04 missed the $0.07 estimate; the company expects more than $100 million of EBITDA improvement in 2026. KeyBanc noted weakening MDI fundamentals and higher input and energy costs, while Huntsman’s shares remain down 36% over six months and its dividend yield is 3.7%.

Analysis

The setup is deal-optionality layered over a still-soft chemicals cycle—not yet evidence of an earnings inflection. HUN’s EPS miss despite stronger revenue, weakening MDI conditions, and higher energy/input costs make near-term margin conversion the key test; revenue alone does not validate the recovery case. The claimed 2026 EBITDA improvement is company outlook, and the article gives no bridge showing how much is recurring cost savings versus volume, pricing, or one-offs.

KeyBanc’s synergy value could support HUN’s equity only if transaction structure, ownership of benefits, financing, and closing conditions are favorable. Those terms are absent here, so the $6/share figure should be treated as a model assumption, not a standalone catalyst. Olin is not automatically a beneficiary on the same per-share basis; its exposure depends on the actual consideration and post-close economics. A delay, adverse terms, or regulatory obstacle could remove deal premium just as weak MDI and cost inflation pressure operating earnings.

Over days, analyst-target revisions may support sentiment, but over 1–3 months the decisive catalysts are verified transaction documents/closing progress and Q4 EBITDA versus the cited $60–80m estimate. Over 6–18 months, the thesis requires delivered, durable savings and stabilization in MDI, not just announced synergies. Contrarian angle: apparent upside to analyst fair values may overstate certainty by capitalizing deal value before terms and execution are independently demonstrated. Falsifiers: a closing delay or changed terms, Q4 EBITDA below the cited range, or continued cost pressure without offsetting savings.

Key Decisions for Investors

• Do not chase HUN solely on target-price increases. Keep exposure neutral until the merger terms, allocation of synergies, financing, and closing conditions are verified; the article does not establish these economics.
• If documentation confirms favorable HUN economics and closing risk is acceptable, consider a small, defined-risk 3–6 month HUN call spread (near-the-money long leg, 15–20% out-of-the-money short leg) rather than an unhedged event bet. Limit premium at risk; avoid sizing off the stated $6/share synergy estimate alone.
• Track Q4 EBITDA against $60–80m and seek a quantified bridge for the >$100m 2026 EBITDA-improvement goal. Reassess the bullish case if Q4 misses that range or savings are not translating into cash earnings while input costs rise.
• Do not pair HUN against Olin until the consideration, exchange economics, and each company’s post-close exposure are clear; the supplied information is insufficient to infer which side captures more value.